Cardurion Pharmaceuticals Bolsters Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer
Strategic Finance Leader Brings Deep Biopharmaceutical Industry Experience and Track Record of Successful Leadership BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Elizabeth Radcliffe as Chief Financial Officer. A […]
Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure
CARDINAL-HF is the first Phase 2 proof-of-concept trial of a PDE9 inhibitor in heart failure Large-scale trial builds upon encouraging data generated in Cardurion’s Phase 1b trial CARDINAL-HF will examine the effects of CRD-740, Cardurion’s PDE9 inhibitor, in both types of heart failure and in key subsets of these patients BOSTON – July 19, 2022 […]
Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer
Brings More Than 30 Years of Pharmaceutical and Biotechnology Leadership Experience Supports Cardurion’s Continued Advancement of Growing Pipeline of Cardiovascular Drug Candidates BOSTON – February 16, 2022 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure […]
Cardurion Pharmaceuticals Announces Investment of up to $300 Million from Bain Capital
Investment to support Cardurion’s further evolution into a cardiovascular leader BOSTON – October 27, 2021 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment […]
Cardurion Pharmaceuticals Announces Appointment of Howard K. Surks, M.D., as Chief Scientific Officer and Head, Translational Medicine
Appointment reflects progress of Company’s early-stage pipeline toward the clinic BOSTON, Mass., December 14, 2020 – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer […]
Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer
Appointment reflects growing strength and diversity of Cardurion’s pipeline July 08, 2020 08:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Chris Morabito, M.D., as chief medical officer […]
Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer
April 15, 2020 07:30 AM Eastern Daylight Time BOSTON – (BUSINESS WIRE) – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Peter S. Lawrence as president and chief executive officer. Mr. Lawrence joins Cardurion after […]
Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
BOSTON, Mass. – November 20, 2019 – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced that it has consummated a private investment from Polaris Partners, a leading healthcare investment firm with a long history of partnering with entrepreneurs […]
Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models
November 12, 2018 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced preclinical results from its study of CRD-733, the company’s novel Phosphodiesterase-9 enzyme (PDE-9) inhibitor, in a poster presentation at the American Heart Association (AHA) […]
Silvia Priori, M.D., Ph.D. Delivers the William Harvey Lecture on Basic Science
CAMBRIDGE, MASS. – [October 2, 2018] – The European Society of Cardiology Congress holds four specialized lectures each year and selects four renowned scientists who are seen by their peers as leading experts in their corresponding fields. The William Harvey Lecture on Basic Science is a noteworthy accolade and recognizes a member of the scientific […]